Rohit Singhania, MD
Gastroenterology · Manchester, CTNPI 1457664500
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Phathom Pharmaceuticals, Inc. at 57.8% of the total. Reporting peaked in 2024 at $23,522 and has fallen 68.4% since, to $7,441 in 2025. Among gastroenterology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 535 payments — averaging $81.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$25K
- AbbVie$6K
- Ferring International Pharmascience Center US$2K
- Janssen Research & Development, LLC$2K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- plus $5K from 26 others
Across 8 payments — averaging $13,725 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$80K
- Janssen Research & Development, LLC$30K
What the payments were for
- Consulting fees$5,00011%
- Speaking & faculty fees$20,25046%
- Travel & lodging$4,60211%
- Food & beverage$13,67431%
- Education$1380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 45 | $25,238 |
| AbbVie | 154 | $6,416 |
| Ferring International Pharmascience Center US | 1 | $2,400 |
| Janssen Research & Development, LLC | 10 | $1,658 |
| Johnson & Johnson(2 entities) | 56 | $1,406 |
| Takeda Pharmaceuticals U.S.A., Inc. | 54 | $1,360 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 51 | $1,090 |
| Bristol Myers Squibb | 38 | $701 |
| Regeneron Healthcare Solutions, Inc. | 11 | $418 |
| Gilead | 14 | $400 |
| Pfizer | 25 | $299 |
| Ironwood Pharmaceuticals, Inc | 10 | $244 |
| Ferring Pharmaceuticals Inc. | 11 | $236 |
| Intercept Pharmaceuticals, Inc. | 8 | $181 |
| Sanofi | 8 | $179 |
| Medtronic | 1 | $124 |
| Amgen | 1 | $121 |
| Janssen Scientific Affairs, LLC | 1 | $117 |
| QOL Medical, LLC | 3 | $111 |
| Echosens North America, Inc. | 4 | $109 |
| Exact Sciences | 4 | $102 |
| Ardelyx, Inc. | 5 | $101 |
| Celltrion USA Inc. | 4 | $95 |
| E.r. Squibb & Sons, L.L.C. | 1 | $95 |
| Boston Scientific | 1 | $95 |
| Madrigal Pharmaceuticals | 3 | $84 |
| Boehringer Ingelheim | 4 | $79 |
| Genentech, Inc. | 1 | $64 |
| Nestle Healthcare Nutrition Inc. | 3 | $58 |
| Cook Medical LLC | 1 | $48 |
| Olympus America Inc. | 1 | $21 |
| Braintree Laboratories, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,665 in reported general payments places this provider in the 90th percentile of 326 gastroenterology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi On-BodyRisankizumab-Rzaa | 13 | $244,542 |
| RinvoqUpadacitinib | 20 | $132,125 |
| XifaxanRifaximin | 11 | $24,047 |
| LinzessLinaclotide | 13 | $20,248 |
| VoqueznaVonoprazan Fumarate | 13 | $14,477 |
| DexilantDexlansoprazole | 13 | $10,179 |
| Omeprazole | 213 | $3,555 |
| Budesonide DrBudesonide | 20 | $2,393 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 14 | $2,301 |
| Famotidine | 54 | $2,251 |
| Pantoprazole Sodium | 146 | $2,149 |
| Mesalamine | 12 | $1,602 |
| Esomeprazole Magnesium | 42 | $1,228 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 20 | $1,039 |
| Lansoprazole | 21 | $939 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Linzess | $6,416 | $152,37233 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,090 | $24,04711 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $25,238 | $14,47713 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $1,360 | $10,17913 claims |
| Braintree Laboratories, Inc.Sutab | $16 | $2,30114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 326 gastroenterology providers in Connecticut.
Other gastroenterology in Manchester
- Paul FeuerstadtHamden$1M
- James FrestonFarmington$772K
- Loren LaineWest Haven$451K
- Martin HoffmanHartford$317K
- Colin SwalesHartford$285K
- Joseph CappaGlastonbury$200K
- Renuka UmashankerHamden$197K
- David HassHamden$173K
- Michael EinsteinHartford$139K
- Pramod MistryNew Haven$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.